NCT00151957View on ClinicalTrials.gov

Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD and Previously Participated in MTS Trials

PHASE3CompletedINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
DRUG

Methylphenidate Transdermal System

MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks

Sponsors

Lead Sponsor

Noven Therapeutics
All Listed Sponsors
collaborator

Noven Pharmaceuticals, Inc.

INDUSTRY

lead

Noven Therapeutics

INDUSTRY